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Abstract
Background Biosimilars are highly similar to the licensed biologic (“reference product”), with no clinically meaningful 
differences in safety, purity, or potency between the two products.
Objective This comparative 52-week clinical study evaluated the efficacy, safety, immunogenicity, pharmacokinetics (PK), 
and pharmacodynamics (PD) of PF-05280586 (Ruxience™ [a rituximab biosimilar]) versus rituximab reference product 
sourced from the EU  (MabThera®; rituximab-EU).
Patients and Methods Subjects with CD20-positive, low-tumor-burden follicular lymphoma (LTB-FL) and an Eastern 
Cooperative Oncology Group performance status 0–1 were randomized (1:1) to PF-05280586 or rituximab-EU (375 mg/m2 
intravenously [once weekly for 4 weeks at days 1, 8, 15, and 22]), stratified using the Follicular Lymphoma International 
Prognostic Index 2 classification. The primary endpoint was overall response rate (ORR) at week 26 (percentage of subjects 
achieving complete response [CR] or partial response [PR]). Therapeutic equivalence was concluded if the two-sided 95% 
confidence interval (CI) for the difference in ORR between groups was within the prespecified margin (± 16%). Secondary 
endpoints included progression-free survival (PFS), CR rate, safety, immunogenicity, PK, and PD.
Results A total of 394 subjects were randomized: PF-05280586 (n = 196) or rituximab-EU (n = 198). ORR at week 26 was 
75.5% (PF-05280586) versus 70.7% (rituximab-EU), for a difference of 4.66%; 95% CI (− 4.16 to 13.47), which was entirely 
within the prespecified equivalence margin. Rates of CR were 29.3% (PF-05280586) versus 31.0% (rituximab-EU). Esti-
mated 1-year PFS rates were 78.2% (95% CI 70.2–84.2) and 83.0% (95% CI 75.0–88.6) for PF-05280586 and rituximab-EU, 
respectively. Safety, immunogenicity, and mean serum concentrations were similar between groups.
Conclusions The efficacy, safety, immunogenicity, PK, and PD of PF-05280586 and rituximab-EU were similar up to week 
52 in subjects with previously untreated CD20-positive LTB-FL.
Clinical Trial Registration ClinicalTrials.gov, NCT02213263 and EudraCT (2014-000132-41).
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Key Points 
PF-05280586 (Ruxience™ [a rituximab biosimilar]) 
and rituximab reference product sourced from the EU 
 (MabThera®; rituximab-EU) (both as monotherapy) dem-
onstrated similar efficacy, safety, immunogenicity, phar-
macokinetics, and pharmacodynamics in this comparative 
clinical study conducted in a suitably sensitive population.
These results are consistent with the similarity between 
PF-05280586 and reference rituximab shown in earlier 
studies.
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product can best be assessed using rituximab monotherapy 
in this setting [5, 6], without confounding factors that could 
potentially arise from treatment in other indications requir-
ing rituximab in combination with chemotherapy.
This comparative clinical study evaluated the efficacy, 
safety, immunogenicity, PK, and pharmacodynamics (PD) 
of PF-05280586 compared with rituximab-EU in subjects 
with previously untreated CD20-positive LTB-FL. We 
report data at study completion (April 19, 2018), when 
the last randomized subject had completed 52 weeks of 
follow-up.
2  Methods
2.1  Study Population
Eligibility criteria were similar to those used in published 
randomized studies of rituximab monotherapy in subjects 
with LTB-FL [13, 14]. Adults (aged ≥ 18 years) with LTB-FL 
without lymphoma-related B symptoms (i.e., fever > 38 °C 
for 3 consecutive days; recurring, drenching night sweats; 
unintentional weight loss exceeding 10% of body weight in 
6 months) were included. Subjects had an Eastern Coopera-
tive Oncology Group performance status of 0–1. LTB was 
assessed using the Groupe d’Etude des Lymphomes Follicu-
laires criteria [15], and CD20-positive FL was confirmed ret-
rospectively by central pathology review (Online Resource 1, 
see the electronic supplementary material [ESM]).
Subjects were excluded from the study if they met any of 
the following criteria: ineligible for rituximab monotherapy, 
evidence of high-grade or diffuse large B-cell lymphoma, 
previous history of T-cell lymphoma, ≥ 5000/mm3 circulat-
ing lymphoma cells, or prior treatment with rituximab or 
other systemic therapy for B-cell NHL. Subjects with severe, 
acute, or chronic active conditions were also excluded from 
the study (Online Resource 2, see the ESM).
2.2  Study Design and Treatments
This was a randomized, double-blind, comparative clinical 
study in subjects with CD20-positive LTB-FL receiving 
first-line treatment, and was conducted at 160 centers in 29 
countries (Online Resource 3, see the ESM).
2.3  Randomization and Masking
Subjects were randomized (1:1) to PF-05280586 or ritux-
imab-EU (375  mg/m2 intravenously [once weekly for 
4 weeks at days 1, 8, 15, and 22]) and followed through to 
week 52 (Fig. 1). Subjects were stratified (low, medium, and 
high risk) at randomization using the Follicular Lymphoma 
International Prognostic Index 2 (FLIPI2) classification 
1 Introduction
Biosimilars are highly similar to the licensed biologic (“ref-
erence product”) such that there are no clinically meaning-
ful differences in safety, purity, or potency [1]. The defini-
tions of biosimilarity differ between the European Union 
(EU) and the United States (US); however, the underlying 
principles are aligned [1, 2]. The development and pathway 
to regulatory approval of biosimilars involves a stepwise 
approach of analytical, comparative physicochemical, and 
in vitro biological evaluation, and nonclinical and clinical 
studies (conducted in a suitably sensitive study population), 
comprising the “totality of the evidence” [1]. Biosimilars are 
expected to offer cost savings and improve access to biologic 
medicines [3, 4]. This may lead to improved management of 
a number of conditions, including hematologic malignancies 
and autoimmune diseases [4].
Rituximab  (Rituxan®;  MabThera®) has an important role 
in the treatment armamentarium for malignant hematology 
and autoimmune diseases [5, 6]. However, access to rituxi-
mab is limited by factors such as availability, reimbursement, 
and insurance coverage. Moreover, patent portfolios for ritux-
imab have expired or are nearing the end of term, which, in 
turn, has prompted the development of biosimilars [3].
Rituximab biosimilars are approved by the European 
Medicines Agency (EMA) [7] and the US Food and Drug 
Administration (FDA) [8]. PF-05280586 (Ruxience™) 
was recently approved by the FDA for the treatment of 
non-Hodgkin’s lymphoma (NHL), chronic lymphocytic 
leukemia (CLL), and granulomatosis with polyangiitis 
and microscopic polyangiitis [9]. PF-05280586 has the 
same primary amino acid sequence as rituximab reference 
products sourced from the US (rituximab-US;  Rituxan®) 
and the EU (rituximab-EU;  MabThera®) [10]. Moreover, 
comparative studies have shown similar structural, func-
tional, and animal toxicity profiles of PF-05280586, ritux-
imab-US, and rituximab-EU [10]. Pharmacokinetic (PK) 
bioequivalence between PF-05280586, rituximab-US, and 
rituximab-EU has been demonstrated in subjects with rheu-
matoid arthritis [11]. This study also demonstrated simi-
lar CD19-positive B-cell depletion, safety, and immuno-
genicity between all treatment groups. An extension phase 
of this study showed acceptable safety, tolerability, and 
immunogenicity [12].
Subjects with previously untreated CD20-positive, low-
tumor-burden follicular lymphoma (LTB-FL) were consid-
ered the most appropriate patient population to demonstrate 
the clinical similarity of PF-05280586 and rituximab-EU 
(both in the first-line setting), and this selection was sup-
ported by regulatory authorities, since it represents a popula-
tion suitably sensitive for distinguishing any potential clini-
cally meaningful differences. Moreover, similarity in clinical 
efficacy between a rituximab biosimilar and the reference 
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[16]. Randomization was conducted using a web-based 
automated-response system.
Concomitant medications were permitted, including pre-
scription and nonprescription drugs, nondrug therapy, and 
dietary supplements and herbal preparations to treat adverse 
events (AEs) or comorbid conditions. Concomitant admin-
istration of any other experimental drug or chemotherapy, 
anticancer hormonal therapy, radiotherapy, or immunother-
apy was not permitted during study participation. Additional 
doses of rituximab after the initial four weekly doses were 
also not permitted.
2.4  Primary Study Objective and Endpoint 
Assessments
The primary objective of the study was to compare the effi-
cacy of PF-05280586 and rituximab-EU. The primary end-
point was overall response rate (ORR) at week 26, defined as 
the percentage of subjects achieving complete response (CR) 
or partial response (PR), based on central review, accord-
ing to the revised response criteria for malignant lymphoma 
[17].
2.5  Secondary Objectives and Endpoint 
Assessments
Secondary endpoints included progression-free sur-
vival (PFS), CR rate at week 26, time to treatment fail-
ure (TTF), duration of response (DOR), overall survival 
(OS), safety, immunogenicity (including events related 
to Standardised MedDRA Queries of anaphylaxis and 
hypersensitivity reactions, and events meeting program-
matically identified Sampson’s criteria) [18], PK, and 
PD. Safety endpoints included type, incidence, severity, 
timing, seriousness and relatedness of AEs, and labora-
tory abnormalities. AEs were graded in accordance with 
the National Cancer Institute Common Terminology Cri-
teria for Adverse Events (version 4.03). AEs of special 
interest were identified based on the established safety 
profile of rituximab.
Immunogenicity endpoints were the percentage of sub-
jects who were positive for antidrug antibodies (ADAs) and 
neutralizing antibodies (NAbs), using a tiered approach 
of screening, confirmation, and titer determination. Two 
semiquantitative electrochemiluminescent ADA assay 
methods were fully validated at QPS, LLC (Newark, Dela-
ware, USA). Serum ADA samples were analyzed for the 
presence or absence of anti-PF-05280586 or anti-rituxi-
mab antibodies using a validated drug-specific assay with 
a tiered approach using screening, confirmation, and titer 
quantitation. Cross-reactivity analysis was conducted for 
samples that tested positive in the assay for the adminis-
tered study drug using the alternate assay, with titration 
and confirmatory analysis.
Two semiquantitative NAb cell-based assay methods 
were fully validated at QPS, LLC. NAb serum samples 
that were ADA-positive were analyzed for the presence or 
absence of neutralizing anti-rituximab antibody and neu-
tralizing anti–PF-05280586 antibody using the validated 
drug-specific assay with a tiered approach using screening, 
confirmation, and titer quantitation. Cross-reactivity analy-
sis was conducted for samples that tested positive in the 
assay for the administered study drug using the alternate 
assay with titration and confirmatory analysis.
For subjects who tested positive for ADA, the titer, time 
of onset, and duration of ADA response were recorded.
PK endpoints were peak and trough drug concentrations. 
PD was evaluated using circulating CD19-positive B-cell 
counts as a marker for CD20-positive B-cells.
Fig. 1  Study design. aSubjects were stratified at randomization (1:1) 
using the FLIPI2 classification and had an ECOG performance sta-
tus of 0–1. bPF-05280586 or rituximab-EU (375 mg/m2 intravenously 
[once weekly for 4 weeks at days 1, 8, 15, and 22]). ECOG Eastern 
Cooperative Oncology Group, FLIPI2 Follicular Lymphoma Interna-
tional Prognostic Index 2, rituximab-EU rituximab reference product 
from the European Union
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2.6  Statistical Methods
A study published by Ardeshna and colleagues is the only 
randomized trial in subjects with asymptomatic FL that 
compared rituximab monotherapy with watchful waiting 
(WW), using the Cheson response criteria [13]. In the study 
by Ardeshna and colleagues, the response rate to rituximab 
therapy (weekly for 4 weeks) was estimated to be 77%, and 
6% in the WW arm at month 7 [13]. The difference (rituxi-
mab − WW) was estimated to be 71% with the 95% confi-
dence interval (CI) of 60–79%. Based on these results, a 
margin of − 16 to 16% would preserve at least 73% efficacy 
based on the lower bound of the 95% CI in the ORR differ-
ence (rituximab − WW).
The primary efficacy endpoint (ORR) was defined as 
the percentage of subjects achieving CR or PR at week 
26. Assuming a week 26 ORR of 77% in both treatment 
groups (the stated equivalence margin), a sample size of 394 
subjects (197 per treatment arm) was estimated to provide 
approximately 93% power to demonstrate equivalence with 
a 2.5% type 1 error rate.
The stratified Miettinen and Nurminen method was used 
to obtain the 95% CI for the estimated difference between 
PF-05280586 and rituximab-EU [19]. The stratified Man-
tel–Haenszel method was used to obtain the correspond-
ing estimated treatment group difference (point estimate). 
Subjects were stratified by the FLIPI2 classification (low, 
medium, and high). Subjects with a missing week 26 
response were imputed as nonresponders in the primary 
analysis.
Equivalence was concluded if the two-sided 95% CI for 
the ORR difference between treatment groups at week 26 
was within the equivalence margin of ± 16%. An additional 
analysis was conducted to test equivalence of the ORR dif-
ference using a margin of ± 14.9% in order to meet regula-
tory requirements.
The intent-to-treat (ITT) population (defined as all subjects 
who were randomized) was considered primary for the analy-
sis of efficacy endpoints. The per-protocol (PP) population 
(defined as all subjects who received at least one dose of study 
treatment to which they were assigned and who had measur-
able disease at baseline and no important protocol deviations) 
was used to assess the sensitivity of the ITT efficacy results. 
The response-evaluable population (defined as all subjects in 
the ITT population who received at least one dose of study 
treatment and who had adequate disease assessment at baseline 
and at least one post-baseline response assessment) was used 
for the analysis of DOR.
A stratified log-rank test (stratified by FLIPI2) was used to 
compare PFS, TTF, DOR, and OS between treatment groups. 
These endpoints were also summarized using Kaplan–Meier 
plots. A Cox model with FLIPI2 categorization as strata was 
used to estimate the hazard ratio (HR) and its 95% CI for the 
treatment effect. CR was analyzed using the same methods as 
for the analysis of ORR.
The safety population (defined as all subjects who received 
at least one dose of study treatment) was used for the safety 
analyses, including AEs, concomitant medication, labora-
tory tests, vital signs, ADA, and NAb incidence and titers. 
The serum concentration–time data were summarized using 
descriptive statistics by treatment (PK population). PD bio-
markers were summarized by treatment and study visit (modi-
fied ITT population).
3  Results
Overall, 394 subjects were randomized to PF-05280586 
(n = 196) or rituximab-EU (n = 198) and comprised the ITT 
population. In total, 393 subjects received at least one dose 
of study drug and were included in the safety population (196 
subjects in the PF-05280586 group and 197 in the rituximab-
EU group) (Fig. 2).
3.1  Baseline Characteristics and Subject Disposition
Demographic characteristics were similar between treatment 
groups. Subjects had a median age of 60.0 years, and 216 out 
of 394 (54.8%) were female. The randomization stratifica-
tion factor was similar between treatment groups. According 
to FLIPI2, 112 subjects (28.4%) had low, 260 (66.0%) had 
medium, and 22 (5.6%) had high risk. Overall, 106 subjects 
(26.9%) had Ann Arbor stage II, 174 (44.2%) had stage III, and 
114 (28.9%) had stage IV disease (Table 1).
3.2  Efficacy
3.2.1  Primary Endpoint
The ORR at week 26 (the primary efficacy endpoint, ITT) 
demonstrated therapeutic equivalence between PF-05280586 
and rituximab-EU. In the ITT population, the ORR at week 
26 was 75.5% (PF-05280586) versus 70.7% (rituximab-
EU) and was identical to the results reported at the primary 
completion date. For the difference in ORR of 4.66%, the 
corresponding 95% CI (− 4.16 to 13.47) was entirely con-
tained within the prespecified equivalence margins of ± 16% 
and ± 14.9% (Table 2). The ORR derived from central review 
assessments in the PP population was consistent with the 
corresponding results for the ITT population. The sensitivity 
analysis using the PP population supported the conclusion 
of the primary endpoint analysis.
Based on observed data at week 26, the analysis of ORR 
within both treatment groups (PF-05280586 and rituximab-
EU) was consistent with the primary analysis. Furthermore, 
at week 26 (based on updates to the central review assessment 
as of the final database lock on May 18, 2018), 51 out of 174 
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subjects (29.3%) versus 57 out of 184 subjects (31.0%) had 
CR in the PF-05280586 and rituximab-EU groups, respec-
tively, and 97 out of 174 subjects (55.7%) in the PF-05280586 
group and 83 out of 184 subjects (45.1%) in the rituximab-EU 
group had PR. A total of 20 out of 174 subjects (11.5%) ver-
sus 36 out of 184 subjects (19.6%) had stable disease in the 
PF-05280586 and rituximab-EU groups, respectively, and six 
out of 174 subjects (3.4%) and eight out of 184 subjects (4.3%) 
had progressive disease (PF-05280586 vs rituximab-EU, 
respectively) (Online Resource 4, see the ESM).
3.2.2  Secondary Endpoints
Based on cumulative data at study completion, estimated 
1-year PFS rates were 78.2% (95% CI 70.2–84.2) and 83.0% 
(95% CI 75.0–88.6) in the PF-05280586 and rituximab-EU 
groups, respectively. The HR for PFS for PF-05280586 
versus rituximab-EU was 1.393 (95% CI 0.847–2.291), 
p = 0.189 (Online Resource 5a, see the ESM). The DOR 
was similar between the two treatment groups. Using a Cox 
proportional hazards model with FLIPI2 categorization as 
strata, the HR for TTF for PF-05280586 versus rituximab-EU 
was 1.163 (95% CI 0.786–1.720), p = 0.450 (Online 
Resource 5b, see the ESM).
3.3  Safety
The incidence of all-causality treatment-emergent adverse 
events (TEAEs) was similar in the two treatment groups 
(79.6% [PF-05280586] vs 73.6% [rituximab-EU]). The 
most frequently reported TEAEs (≥ 2% of subjects in either 
group) were infusion-related reactions (IRRs) (25.0% vs 
29.9%), pruritus (6.6% vs 11.2%), and headache (8.2% 
vs 9.6%) (PF-05280586 vs rituximab-EU, respectively) 
(Table 3). In total, there were 28 out of 196 subjects (14.3%) 
in the PF-05280586 group and 26 out of 197 subjects 
(13.2%) in the rituximab-EU group with a TEAE reported 
at grade 3 or higher. The incidence of serious AEs was simi-
lar between groups (8.7% and 7.6% in the PF-05280586 and 
rituximab-EU groups, respectively). All-causality grade 3 
TEAEs were reported in 13.8% (PF-05280586) versus 12.2% 
(rituximab-EU) of subjects. The most frequently reported 
grade 3 TEAEs were IRRs (2.0% vs 0.5%) and hyperten-
sion (1.0% vs 2.0%) in the PF-05280586 and rituximab-EU 
groups, respectively.
Treatment-related TEAEs were similar between groups 
(Online Resource 6, see the ESM). A total of four subjects 
reported five treatment-related serious AEs. These were 
grade 3 pyrexia and grade 3 Clostridium difficile infection in 
Fig. 2  Subject disposition. n number of subjects, N total number of subjects randomized, PK pharmacokinetic, rituximab-EU rituximab refer-
ence product from the European Union
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the PF-05280586 group, and grade 3 serum sickness, grade 3 
IRR, and grade 2 dyspnea in the rituximab-EU group. Over-
all, 86 subjects (43.9%) in the PF-05280586 group and 94 
subjects (47.7%) in the rituximab-EU group reported treat-
ment-related TEAEs, a total of 258 in each treatment group. 
The most frequently reported treatment-related TEAEs were 
IRRs (49 subjects [25.0%] in the PF-05280586 group and 
59 subjects [29.9%] in the rituximab-EU group) and pruri-
tus (ten subjects [5.1%] in the PF-05280586 group and 18 
subjects [9.1%] in the rituximab-EU group).
The incidence of grade 3 treatment-related TEAEs was 
similar between groups (4.6% [PF-05280586] vs 3.6% 
[rituximab-EU]). One treatment-related TEAE (grade 4 
neutropenia) was reported in one subject in the rituximab-EU 
group, but was not associated with any signs or symptoms 
of infection. No subjects in the PF-05280586 group reported 
grade 4 treatment-related TEAEs. Two deaths occurred dur-
ing the study (one in each group) due to disease progression, 
and were deemed not to be treatment-related.
TEAEs of special interest were similar between treatment 
groups. The most frequently reported TEAEs of special 
interest were IRRs (Online Resource 7, see the ESM). There 
were no reports of tumor lysis syndrome or progressive mul-
tifocal leukoencephalopathy in either treatment group. No 
clinically significant differences in laboratory values or vital 
signs were observed between the two treatment groups.
In total, 54 subjects (13.7%) discontinued the study (26 
out of 196 subjects [13.3%] in the PF-05280586 group and 
28 out of 198 subjects [14.1%] in the rituximab-EU group) 
(Online Resource 8, see the ESM). No subjects in either 
treatment group reported an AE that led to a dose reduction. 
In total, 37 subjects (18.9%) in the PF-05280586 group and 
51 (25.9%) in the rituximab-EU group experienced AEs that 
led to an infusion interruption.
3.4  Immunogenicity
Prior to initiation of study drugs at baseline (day 1), 7.2% 
of subjects in the PF-05280586 group and 8.7% of sub-
jects in the rituximab-EU group had a positive ADA test 
(titer ≥ 1.88). The ADA titers were low in these positive 
pre-dose samples. Prior to dosing on day 15, there was no 
increase in ADA titers, indicating that a booster response 
was not observed. The ADA titers reported at week 13 and 
beyond did not increase and further confirmed the absence 
of a booster response.
Overall, 22.1% and 19.8% of subjects in the PF-05280586 
and rituximab-EU groups, respectively, tested positive 
for ADA, post-dose. Of the samples that tested positive 
for ADA, the majority were positive in both ADA assays 
(anti–PF-05280586 or anti-rituximab antibodies), with 
93.0% of subjects with positive ADA cross-reactivity in the 
PF-05280586 group and 76.9% in the rituximab-EU group 
(Online Resource 9, see the ESM). No ADA-positive sub-
jects were positive for NAbs. No clinically meaningful dif-
ferences were observed in immune-related AEs in subjects 
who were treatment-emergent ADA-positive versus those 
who were ADA-negative.
The percentage of IRRs in ADA-positive subjects was 
25.6% in both treatment groups. Events of anaphylaxis/
hypersensitivity (broad and narrow Standardised Med-
DRA Query) in ADA-positive subjects were similar in 
both treatment groups (16.3% [PF-05280586] vs 12.8% 
[rituximab-EU]). Events potentially meeting Sampson’s 
criteria in ADA-positive subjects were also similar (11.6% 
 [PF-05280586] vs 10.3% [rituximab-EU]).
Table 1  Baseline subject demographic and clinical characteristics 
(ITT population)a
ECOG Eastern Cooperative Oncology Group, FLIPI2 Follicular 
Lymphoma International Prognostic Index 2, ITT intent-to-treat, 
rituximab-EU rituximab reference product from the European Union, 
SD standard deviation
a All subjects who were randomized to treatment
b ECOG status not reported for one subject in the rituximab-EU group
Baseline characteristics PF-05280586 
N = 196
Rituximab-EU
N = 198
Demographic
 Gender, n (%)
  Female 110 (56.1) 106 (53.5)
  Male 86 (43.9) 92 (46.5)
 Age, mean (SD), years 58.7 (12.1) 58.3 (12.8)
 Body mass index, mean (SD), 
kg/m2
26.7 (4.8) 26.3 (5.2)
 Race, n (%)
  White 158 (80.6) 146 (73.7)
  Black 1 (0.5) 0
  Asian 30 (15.3) 44 (22.2)
  Other 7 (3.6) 8 (4.0)
 Ethnicity, n (%)
  Hispanic/Latino 31 (15.8) 26 (13.1)
  Not Hispanic/Latino 165 (84.2) 172 (86.9)
Clinical characteristics
 Ann Arbor stage, n (%)
  I 0 0
  II 52 (26.5) 54 (27.3)
  III 89 (45.4) 85 (42.9)
  IV 55 (28.1) 59 (29.8)
 ECOG performance status, n (%)b
  0 171 (87.2) 169 (85.4)
  1 25 (12.8) 28 (14.1)
 FLIPI2 risk classification, n (%)
  Low 54 (27.6) 58 (29.3)
  Medium 133 (67.9) 127 (64.1)
  High 9 (4.6) 13 (6.6)
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3.5  Pharmacokinetics
Mean serum concentrations of PF-05280586 and rituximab-EU 
were similar. The peak mean serum concentrations were 
observed at day 22, within 15 min before the end of the infu-
sion, and were similar between the two treatment groups. No 
notable differences were observed in mean serum concentra-
tions between ADA-positive and ADA-negative subjects in 
either treatment group (Online Resource 10, see the ESM).
3.6  Pharmacodynamics
In both treatment groups, rapid depletion in CD19-positive 
B-cell counts was observed after initial dosing, with initial 
recovery by week 39 and a sustained increase until the end 
of week 52 (Online Resource 11, see the ESM).
4  Discussion
This study demonstrated therapeutic equivalence between 
PF-05280586 and rituximab-EU at week 26 for the pri-
mary efficacy endpoint, ORR, in subjects with previously 
untreated CD20-positive LTB-FL. The 95% CI for the differ-
ence for ORR was entirely contained within the prespecified 
equivalence margins. Based on the central review assess-
ments as of the final database lock, there were no clinically 
meaningful or statistically significant differences in CR rate 
at week 26, PFS, DOR, or TTF, all of which were similar 
between treatment groups. PF-05280586 and rituximab-EU 
showed similar safety profiles. The safety profile of 
PF-05280586 was similar to the established safety profile 
of rituximab-EU [5, 6]. The immunogenicity, PK, and PD 
of PF-05280586 and rituximab-EU were similar during the 
study. Rapid depletion in CD19-positive B-cell counts was 
observed following initial dosing, with similar results in both 
treatment groups followed by recovery.
The development of PF-05280586 as a biosimilar to ritux-
imab-EU is supported by a body of analytical, nonclinical, 
and clinical data that assess comparative similarity between 
the two products, which comprises the totality of the evidence 
[10–12, 20]. The analytical assessment supports the conclu-
sion that PF-05280586 is highly similar to rituximab-EU 
and that the minor differences do not impact the in vitro 
biological activity of these products, and is unlikely to be 
clinically relevant [10]. Nonclinical toxicity data support 
the totality of the evidence that PF-05280586 is similar to 
rituximab-EU [10]. Results of the in vitro assays demon-
strated that PF-05280586, rituximab-US, and rituximab-EU 
are highly similar in attributes relevant to the known mecha-
nisms of action [10]. In addition, clinical comparability stud-
ies showed similar PK profiles of PF-05280586 and the refer-
ence rituximab products in subjects with rheumatoid arthritis 
[11, 12] and in those with LTB-FL. Similar efficacy profiles 
were also observed for PF-05280586 and rituximab-EU 
in this comparative clinical study in subjects with LTB-FL. 
Finally, similar immunogenicity profiles were observed for 
PF-05280586 and rituximab-EU in the current study, and no 
new safety concerns were identified. The clinical similar-
ity assessment supports the conclusion that PF-05280586 
is similar to rituximab-EU. Based on the totality of the evi-
dence, the FDA granted approval of PF-05280586 for the 
Table 2  Overall response rate at week  26a (central review assessment)
CI confidence interval, CR complete response, ITT intent-to-treat, PP per-protocol, PR partial response, rituximab-EU rituximab reference prod-
uct from the European Union
a Based on the central review assessments as of the final database lock on May 18, 2018
b Subjects missing their week 26 radiology assessments were imputed as nonresponders
c Defined as the percentage of subjects achieving CR or PR, based on central review
d ITT population
e PP population
Endpoint PF-05280586 Rituximab-EU Difference (PF-05280586 
minus rituximab-EU)
ITT population
 Number of subjects 196 198
 Overall response rate, n (%)b,c,d 148 (75.5) 140 (70.7) 4.66
  (95% CI) (68.9–81.4) (63.8–76.9) (− 4.16 to 13.47)
PP population
 Number of subjects 166 176
 Overall response rate, n (%)b,c,e 143 (86.1) 138 (78.4) 7.49
  (95% CI) (79.9–91.0) (71.6–84.2) (− 0.67 to 15.80)
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treatment of NHL, CLL, and granulomatosis with polyangii-
tis and microscopic polyangiitis [9].
One potential limitation of the current study is that it does 
not show that PF-05280586 is equivalent in every indica-
tion for which rituximab is approved; however, this was not 
the aim of the study and is not required for the regulatory 
approval of a biosimilar [1, 2]. In addition, the interpretation 
of AE data is limited due to the relative size of the current 
study; indeed, the safety of a biosimilar relies on a finding 
of biosimilarity and the safety profile of the reference prod-
uct across the indications for which it is approved. Another 
potential limitation of the current study is that subjects 
received four doses of PF-05280586 or rituximab-EU; this 
is in contrast to eight doses of rituximab in aggressive lym-
phomas or 16–20 doses of rituximab in indolent lymphomas 
as induction and maintenance therapy [6, 21].
Treatment options for LTB-FL include WW and rituxi-
mab monotherapy [22]. This study was designed based on 
a randomized clinical trial that compared rituximab mono-
therapy (weekly dosing for 4 weeks) with WW, using the 
revised response criteria for malignant lymphoma [13]. 
After 7 months, the estimated response rate was 77% in the 
rituximab group versus 6% in the WW group, with an esti-
mated difference of 71% (95% CI 60–79) [13]. In the study 
Table 3  Treatment-emergent adverse events (all-causality, ≥ 2%) 
(safety population)
Category PF-05280586 
N = 196
n (%)
Rituximab-EU 
N = 197
n (%)
Subjects with AE 156 (79.6) 145 (73.6)
Injury, poisonings, and proce-
dural complications
61 (31.1) 65 (33.0)
 Infusion-related reaction 49 (25.0) 59 (29.9)
 Fall 5 (2.6) 2 (1.0)
Gastrointestinal disorders 58 (29.6) 52 (26.4)
 Nausea 15 (7.7) 17 (8.6)
 Diarrhea 14 (7.1) 12 (6.1)
 Abdominal pain upper 9 (4.6) 5 (2.5)
 Constipation 8 (4.1) 8 (4.1)
 Abdominal pain 8 (4.1) 3 (1.5)
 Vomiting 3 (1.5) 7 (3.6)
 Dyspepsia 5 (2.6) 2 (1.0)
Infections and infestations 52 (26.5) 63 (32.0)
 Upper respiratory tract infec-
tion
9 (4.6) 5 (2.5)
 Nasopharyngitis 5 (2.6) 9 (4.6)
 Urinary tract infection 5 (2.6) 5 (2.5)
 Sinusitis 5 (2.6) 2 (1.0)
 Influenza 4 (2.0) 6 (3.0)
 Pharyngitis 4 (2.0) 4 (2.0)
 Bronchitis 3 (1.5) 7 (3.6)
Respiratory, thoracic, and medi-
astinal disorders
46 (23.5) 56 (28.4)
 Throat irritation 14 (7.1) 10 (5.1)
 Cough 11 (5.6) 11 (5.6)
 Oropharyngeal pain 2 (1.0) 10 (5.1)
 Dyspnea 6 (3.1) 9 (4.6)
 Oropharyngeal discomfort 4 (2.0) 1 (0.5)
General disorders and adminis-
tration-site conditions
52 (26.5) 53 (26.9)
 Fatigue 12 (6.1) 13 (6.6)
 Asthenia 9 (4.6) 13 (6.6)
 Pyrexia 12 (6.1) 11 (5.6)
 Edema peripheral 2 (1.0) 7 (3.6)
 Influenza-like illness 2 (1.0) 4 (2.0)
Skin and subcutaneous tissue 
disorders
39 (19.9) 47 (23.9)
 Pruritus 13 (6.6) 22 (11.2)
 Rash 10 (5.1) 8 (4.1)
 Erythema 7 (3.6) 2 (1.0)
 Urticaria 3 (1.5) 6 (3.0)
Musculoskeletal and connective-
tissue disorders
38 (19.4) 42 (21.3)
 Back pain 8 (4.1) 10 (5.1)
 Myalgia 9 (4.6) 5 (2.5)
 Pain in extremity 7 (3.6) 4 (2.0)
 Arthralgia 7 (3.6) 6 (3.0)
Subjects were only counted once per treatment for each row. Events 
are displayed by MedDRA (v21.0) system organ class and preferred 
term
AE adverse event, n number of subjects, N total number of subjects 
receiving treatment in each group, rituximab-EU rituximab reference 
product from the European Union
Table 3  (continued)
Category PF-05280586 
N = 196
n (%)
Rituximab-EU 
N = 197
n (%)
Nervous system disorders 34 (17.3) 33 (16.8)
 Headache 16 (8.2) 19 (9.6)
 Dizziness 2 (1.0) 6 (3.0)
Psychiatric disorders 15 (7.7) 17 (8.6)
 Insomnia 5 (2.6) 8 (4.1)
 Anxiety 6 (3.1) 7 (3.6)
Investigations 15 (7.7) 14 (7.1)
 Neutrophil count decreased 5 (2.6) 0
 White blood cell count 
decreased
4 (2.0) 1 (0.5)
Vascular disorders 11 (5.6) 15 (7.6)
 Hypertension 5 (2.6) 7 (3.6)
 Flushing 1 (0.5) 4 (2.0)
Metabolism and nutrition 
disorders
13 (6.6) 12 (6.1)
 Hyperglycemia 1 (0.5) 4 (2.0)
Cardiac disorders 7 (3.6) 9 (4.6)
 Palpitations 5 (2.6) 2 (1.0)
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conducted by Ardeshna and colleagues, the rituximab induc-
tion group (ORR at month 7: 77%) was closed earlier than 
the rituximab maintenance group (ORR at month 7: 88%) 
[13]. However, in the current study, retreatment following 
progression was not precluded and was consistent with a 
randomized phase III study comparing two rituximab dos-
ing strategies for LTB-FL [14]. The ORR observed with 
the rituximab-EU group (76%; observed data at week 26) 
in the current study was consistent with the ORR observed 
in the study conducted by Ardeshna and colleagues (77%; 
observed data at month 7), showing good reproducibility of 
results across the two trials for the rituximab-EU (control) 
groups [13]. In addition, the subject eligibility criteria in this 
study were similar to other randomized studies conducted 
with rituximab monotherapy in the LTB-FL setting [13, 14].
In contrast to this comparative study of PF-05280586 and 
rituximab-EU (each as monotherapy), two approved rituxi-
mab biosimilars (CT-P10 and L01XC02) were studied in 
combination with chemotherapy in patients with FL [23, 
24]. A second study by Ogura and colleagues of CT-P10 or 
rituximab as monotherapy was subsequently performed in 
subjects with previously untreated CD20-positive LTB-FL, 
in order to demonstrate biosimilarity without the confound-
ing effects of chemotherapy [25]. In this study, patients who 
had disease control after the induction period progressed 
to maintenance treatment with CT-P10 or rituximab (every 
8 weeks for six cycles) and, if completed, a second year 
of maintenance treatment of CT-P10 was offered [25]. 
That design was in contrast to this comparative study of 
PF-05280586 and rituximab-EU (each administered as 
monotherapy, in line with current standard of care for LTB-
FL) [22]. As such, this reduces the potentially confounding 
factors that could arise from rituximab in combination with 
chemotherapy, as observed in other pivotal studies of rituxi-
mab biosimilars [23, 24]. The study by Ogura and colleagues 
was different in design to the current study and may account 
for the differences in ORR between the two studies [25]. In 
the study by Ogura and colleagues, as CT-P10 was used as a 
maintenance regimen, higher ORR (81%) was observed with 
rituximab-EU, whereas in the current study, PF-05280586 
was administered as an induction regimen, without a mainte-
nance phase, with an ORR of 71% with rituximab-EU [25]. 
Indeed, the differences in ORR between these two studies 
can also be explained by differences in patient characteristics 
and statistical variations.
In conclusion, this study demonstrated therapeutic 
equivalence between PF-05280586 and rituximab-EU for 
the primary efficacy endpoint, ORR at week 26, and similar 
safety, immunogenicity, PK, and PD in both groups up to 
week 52 in subjects with previously untreated CD20-positive 
LTB-FL.
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